Alerts will be sent to your verified email
Verify Email
DLCL
|
Dr Lalchandani Labs
|
Global Longlife Hosp
|
Transgene Biotek
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
2.53 % | 6.24 % | -34.5 % |
|
5yr average Equity Multiplier
|
1.69 | 1.57 | 11.14 |
|
5yr Average Asset Turnover Ratio
|
0.43 | 0.54 | 0.0 |
|
5yr Avg Net Profit Margin
|
1.96 % | 8.63 % | -5919.21 % |
|
Price to Book
|
1.41 | 0.56 | 1.85 |
|
P/E
|
34.71 | 77.31 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
103.23 Days | -351.43 Days | 59.29 Days |
|
Inventory Days
|
78.71 Days | 11.26 Days | 166.26 Days |
|
Days Receivable
|
408.23 Days | 716.69 Days | 11.76 Days |
|
Days Payable
|
262.63 Days | 489.79 Days | 259.7 Days |
|
5yr Average Interest Coverage Ratio
|
3.16 | 2.59 | -19.2 |
|
5yr Avg ROCE
|
5.08 % | 12.16 % | -3.86 % |
|
5yr Avg Operating Profit Margin
|
14.13 % | -132.06 % | -527.18 % |
|
5 yr average Debt to Equity
|
0.48 | 0.48 | 1.02 |
|
5yr CAGR Net Profit
|
-16.1 % | -37.22 % | -42.08 % |
|
5yr Average Return on Assets
|
1.95 % | 3.07 % | -3.77 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
31.15 % | 35.44 % | 23.64 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-29.63 % | -18.85 % | 0.0 |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Dr Lalchandani Labs
|
Global Longlife Hosp
|
Transgene Biotek
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|